Your guide to peptide science
The education behind our peptide content
Dr. Greene is one of a select few pharmacists in the country to hold A4M Peptide Therapy Certification. He leads Evergreen's education program — translating current peptide science into rigorous, expert-level learning content. His focus is on education, not patient care: arming our community with depth, context, and the standards behind every topic we cover.
- PharmD
- FMCP — Institute for Functional Medicine board certified
- A4M Peptide Certified
"Patients deserve peptides with expert physician guidance and licensed pharmacy quality-controls, not unregulated online gray market sources that put them at great risk."
Medically Reviewed articles
DSIP (Emideltide) Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted against recommending DSIP (Emideltide) for the FDA Section 503A Bulks List. Compounding is not authorized — here's where things stand.
MOTS-c Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend MOTS-c for the FDA Section 503A Bulks List. Compounding is not yet legal — here's exactly where things stand.
A Note From Evergreen on the July 2026 PCAC Peptide Review
Our statement on the FDA Pharmacy Compounding Advisory Committee's July 23–24, 2026 review of seven peptides — six recommended, one rejected. None are legal to compound today.
Semax Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend Semax for the FDA Section 503A Bulks List. Compounding is not yet legal — here's exactly where things stand.
TB-500 Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend TB-500 for the FDA Section 503A Bulks List. Compounding is not yet legal — here's exactly where things stand.
BPC-157 Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted 8-6 to recommend BPC-157 for the FDA Section 503A Bulks List. Compounding is not yet legal — here's exactly where things stand.
Epitalon Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend Epitalon for the FDA Section 503A Bulks List. Compounding is not yet legal — here's exactly where things stand.
KPV Regulatory Status: What the July 2026 FDA Advisory Committee Vote Means
PCAC voted to recommend KPV for the FDA Section 503A Bulks List. Compounding is not yet legal — here's exactly where things stand.